

INTERVENTIONAL VASCULAR THERAPY

Silver Graft

NEXT GENERATION OF ANTIMICROBIAL VASCULAR PROSTHESES

NEXT GENERATION OF ANTIMICROBIAL VASCULAR PROSTHESES

VASCULAR GRAFT INFECTION

Despite the use of prophylactic antibiotics in vascular surgery, the infection rate remains 2 – 5%. Many of these vascular graft infections occur at three months or later. If infected the amputation rate lies between 15 – 60% and the mortality rate exceeds 25%. Besides Staphylococcus spec. a broad spectrum of microorganisms can cause graft infections. ^{1, 2} With the approach to prevent bacterial colonization after implantation and to reduce the risk of late infection, Silver Graft was developed.

WHY SILVER?

- Effective in low concentration: Inactivates DNA replication, protein biosynthesis and membrane potential of microorganisms ³
- Broad spectrum of efficacy
- No documented silver resistance of pathogenic microorganisms³
- Efficacy against increasingly detected methicillinresistant Staphylococcus aureus (MRSA) 4, 4a



Inui, Tazo; Bandyk, Dennis F. (2015): Vascular surgical site infection: risk factors and preventive measures. In: Seminars in vascular surgery 28 (3-4), S. 201–207.

Zühlke, Helmut; Halloul, Zuhir; Zippel, Roland (Hg.) (2019): Septische Gefäßmedizin. Stuttaart. New York. Stuttaart: Geora Thieme Verlaa: Thieme.

³ Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev. 2003 Jun;27(2-3):341-53.


REDUCTION OF BACTERIAL GROWTH



SILVER GRAFT SIGNIFICANTLY REDUCES BACTERIAL GROWTH IN VITRO AND IN VIVO

Both the extent of biofilm formation and the proportion of viable biofilm cells were significantly diminished on the surface of Silver Graft ^{4, 5}

INCUBATION WITH STAPHYLOCOCCUS AUREUS 4



Strathmann M, Wingender J. 2004. Use of an oxonol dye in combination with confocal laser scanning microscopy to monitor damage to Staphylococcus aureus cells during colonization of silver-coated vascular grafts. Intern J Antimicrobial Agents, 24: 234-240.


Wilson, Walter R.; Bower, Thomas C.; Creager, Mark A.; Amin-Hanjani, Sepideh; O'Gara, Patrick T.; Lockhart, Peter B. et al. (2016): Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association. In: Circulation 134 (20), e412-e460.

NEXT GENERATION OF ANTIMICROBIAL VASCULAR PROSTHESES

SILVER IN COATING IS GOLD IN PROTECTION

WHY SILVER GRAFT?

- Facilitates long term inhibition of bacterial colonization due to direct embedding of silver in the textile fabrics ⁴
- Significantly reduces the adhesion of microorganisms in vitro and in vivo ⁵
- Supports gentle and natural healing 5




⁵ Ueberrueck T, Zippel R, Tautenhahn J, Gastinger I, Lippert H, Wahlers T. 2005. Vascular graft infections: in vitro and in vivo investigations of a new vascular graft with longterm protection. J Biomed Mater Res B Appl Biomater, 74(1):601-607. Designed for prophylactic long term protection against vascular graft infections.

FACILITATION OF LONG TERM PREVENTION



To enable an effective long term protection the silver coating is directly embedded in the textile fabric of the prosthesis. Silver Graft retains approx. 98 % of its silver load after one year under laboratory conditions. ⁶

ELUTION OF SILVER OVER TIME ⁶




⁶ Ueberrueck T, Meyer L, Zippel R, Nestler G, Wahlers T, Gastinger I. 2005. Healing Characteristics of a New Silver-Coated, Gelatine Impregnated Vascular Prosthesis in the Porcine Model. Zentralbl Chir, 130:71–76.

INNOVATIONS FOR VASCULAR SURGERY

DESIGNED FOR PROPHYLACTIC LONG TERM PROTECTION

IMPACT OF SILVER IONS ON BACTERIA 7




Kędziora A, Speruda M, Krzyżewska E, Rybka J, Łukowiak A, Bugla-Płoskońska G. Similarities and Differences between Silver Ions and Silver in Nanoforms as Antibacterial Agents. Int. J. Mol. Sci. 2018, 19(2), 444. Silver Graft significantly reduces bacterial growth in vitro and in vivo 4,5

- REDUCES THE ADHESION OF BACTERIA IN VITRO / IN VIVO 4,5
- PROTECTS AGAINST MICROORGANISMS IN VITRO / IN VIVO 4, 5
- DESIGNED FOR LONG-TERM INHIBITION OF VASCULAR GRAFT INFECTION
- CAN IMPLANTED PROPHYLACTICALLY AS PROTECTION AGAINST VASCULAR GRAFT INFECTION
- ADDITIONAL SOAKING IN ANTIBIOTICS (E. G. RIFAMPICIN) IS POSSIBLE
- EXHIBITS EXCELLENT BIOCOMPATIBILITY 6
- SUPPORTS COMPLICATION FREE HEALING ⁶
- MRI COMPATIBLE



NEXT GENERATION OF ANTIMICROBIAL VASCULAR PROSTHESES



STRAIGHT TUBES

Usable Length (cm)	Diameter (mm)	Product Code	
	8	1108000	
	10	1108030	
	12	1108032	
	14	1108034	
15	16	1108001	
	18	1108002	
	20	1108003	
	22	1108042	
	24	1108044	
	8	1108004	
	14	1108005	
	16	1108006	
30	18 1108007		
	20 1108008		
	22 1108062		
	24	1108064	
40	6	1108009	
	7	1108010	
	8	1108011	
	10	1108050	
	12	1108052	
60	6	1108012	
	7 1108013		
	8 1108014		

HELIX SUPPORTED

Usable Length (cm)	Diameter (mm)	Product Code	
30	8	1108026	
40	8	1108027	
60	6	1108022	
	8	1108023	
90	6	1108024	
	8	1108025	

BIFURCATIONS

Usable Length (cm)	Diameter (mm)	Product Code	
40	12 x 6	1108021	
	14 x 7	1108017	
	16 x 8	1108015	
	18 x 9	1108016	
	20 x 10	1108018	
	22 x 11	1108019	
	24 x 12	1108020	

AXILLO-BIFEMORAL

Usable Length (cm)	Diameter (mm)	Product Code	
90/60	8	1108080	

NOTES





Manufacturer

Aesculap AG | Am Aesculap-Platz | 78532 Tuttlingen | Germany C€ 0123

Distributor

B. Braun Melsungen AG | Vascular Systems | Sieversufer 8 | 12359 Berlin | Germany Phone +49 30 568207-300 | Fax +49 30 568207-130 | www.bbraun.com